 |
      
|
|
|
|
|
|||||
|
|
May 30, 2003
Neurochem to present at the Annual UBS Warburg Global Specialty
Pharmaceuticals Conference. About Neurochem
Neurochem is a product-driven, specialty pharmaceutical company offering a new class of
drug candidates to prevent and stop the progression of diseases for which no cure exists.
The Company's strong and growing pipeline aims at fulfilling unmet medical needs and is
focused on disorders of the central nervous system and amyloid-related diseases.
Neurochem's most advanced drug candidate is Fibrillex™, currently in pivotal Phase
II/III clinical development for the treatment of secondary AA amyloidosis, a fatal
disease. Two other programs include Alzhemed™, which has completed a Phase II
clinical trial for the treatment of Alzheimer's disease; and Cerebril™, which is
undergoing a Phase II clinical trial for the treatment of hemorrhagic stroke due to
cerebral amyloid angiopathy. At the pre-clinical development stage, the Company has an
innovative neurological program aimed at treating epileptic seizures induced by traumatic
brain injury. (www.neurochem.com).
All of the statements contained in this news release, other than statements of fact which
are independently verifiable at the date hereof, are forward-looking statements. Such
statements, based as they are on the current expectations of management, inherently involve
numerous risks and uncertainties, known and unknown. Some examples of known risks are: the
impact of general economic conditions, general conditions in the pharmaceutical industry, changes
in the regulatory environment in the jurisdictions in which Neurochem does business, stock
market volatility, fluctuations in costs, and changes to the competitive environment due to
consolidation or otherwise. Consequently, actual future results may differ materially from
the anticipated results expressed in the forward-looking statements.
For further Information, please contact: |
 |
|
 |
|
Our site is best viewed with IE4+ at a resolution of 1024×768. |
|
